BioCryst Pharmaceuticals, Inc.
7.65USD
-0.1300 (-1.67%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BCRX.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Price
Reading the stored fundamentals…
Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.
Is the price low against peers, cash flow and analyst targets?
Do analysts expect earnings and revenue to keep growing?
Only 3 of 6 checks could be assessed because too few analysts cover it and there is no analyst coverage stored; 4 are needed.
Has the business grown and earned good returns on its filed numbers?
2 of 6 checks could not be assessed (the figures they need are not meaningful here).
Can the balance sheet carry its debt?
Is the dividend decent, covered and steady?
No dividend appears in the stored data, so this axis is left off the shape rather than drawn as zero.
An axis marked n/a has no vertex: it is left out of the shape rather than drawn as zero.
Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.
P/E below peers
Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.
Loss-making over the last twelve months, so there is no P/E to compare.
Did not pass
PEG ratio
The PEG ratio is positive and at most 1.5.
PEG 9.39.
Did not pass
EV/EBITDA below peers
EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.
EV/EBITDA 5.6 against a peer median of 12.0 (8 USD companies in Drug Manufacturers - Specialty & Generic).
Passed
Price/book below peers
Price to book is positive and below the peer median, with peers chosen as for P/E.
Book value is negative (liabilities exceed assets), so there is no price/book to compare.
Did not pass
Statements: SEC filings, newest period 06/2026.
Peers: P/E against 5 USD companies in Drug Manufacturers - Specialty & Generic; EV/EBITDA against 8 USD companies in Drug Manufacturers - Specialty & Generic; price/book against 10 USD companies in Drug Manufacturers - Specialty & Generic.
Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms
Free cash flow yield
Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.
Free cash flow yield 19.1% against a 4.5% risk-free rate.
Passed
Analyst target above price
The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.
Mean analyst target above the last close by 168.6% (11 analysts).
Passed
Earnings growth, next year
Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.
Only 2 analysts behind the estimate; 3 are needed.
Not assessed
Earnings growth, this year
Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.
Only 2 analysts behind the estimate; 3 are needed.
Not assessed
Revenue growth, next year
Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.
Next year's revenue: consensus up 3.7% (9 analysts).
Did not pass
Revenue growth, this year
Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.
This year's revenue: consensus down 18.8% (10 analysts).
Did not pass
Estimates rising
More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.
No analyst estimates are stored for this security.
Not assessed
Revenue growth, latest quarter
Revenue in the latest quarter is at least 8% above the same quarter a year earlier.
Latest-quarter revenue up 33.6% on a year earlier.
Passed
Earnings growth, multi-year
Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).
Net income was not positive in FY2020, so there is no base to grow from.
Not assessed
Earnings growth, last year
Net income over the latest twelve months is above the twelve months before it, and positive.
Net income was still a loss (twelve months to 06/2026).
Did not pass
Revenue growth, multi-year
Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).
Revenue grew 117.9% a year, FY2020 to FY2025.
Passed
Return on equity
Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.
Return on equity is not meaningful: equity is not positive.
Not assessed
Return on assets
Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.
Return on assets -75.8%: twelve-month net income over the average assets.
Did not pass
Cash earnings
Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.
Operating cash flow was at or above net income over the last twelve months.
Passed
Current ratio
Current assets are at least 1.0x current liabilities. Not applied to financial companies.
Current ratio 2.3x.
Passed
Short-term assets cover long-term liabilities
Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.
Current assets are 0.6x the liabilities due after a year.
Did not pass
Debt to equity
Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.
Equity is negative while the company carries debt.
Did not pass
Net debt to EBITDA
Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.
Net debt with no positive EBITDA to service it.
Did not pass
Interest cover
Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.
Operating income was not positive.
Did not pass
Cash flow to debt
Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.
Operating cash flow is 45.0% of total debt.
Passed
Dividend yield
The dividend yield is at least 2%.
No dividend appears in the stored data.
Not assessed
Payout ratio
Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.
No dividend appears in the stored data.
Not assessed
Free cash flow cover
Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.
No dividend appears in the stored data.
Not assessed
Paid every year
A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.
No dividend appears in the stored data.
Not assessed
No cuts
Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.
No dividend appears in the stored data.
Not assessed
Growing dividend
Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.
No dividend appears in the stored data.
Not assessed